| Yang Zou,Linhan Yang,Jiahui Zhu1,Jihua Fan,Hanrun Zheng,Xiang Liao,Arthur Konnerth,Chunqing Zhan,Yun Zhang Zhiqi Yang,Kuan Zhang,Hongbo Jia,Sunny C Li6,Xiaowei Chen
|
 Alzheimers disease (AD) is a progressive neurodegenerative
disorder, primarily characterized by a gradual decline in cognitive
function. The most typical pathological hallmark of A? is
amyloid-beta plaques. In recent years, numerous
monoclonal antibodies targeting brain A? have entered clinical
trials. Among them, donanemab and lecanemab have shown
remarkable efficacy in clearing AB plaques from the brain of AD
patients. However, the improvement in cognitive abilities is
limited, as they might not reverse the neuronal impairments
that have occurred widely in the brain networks. Clearly, lessons
learned from these clinical trials suggest that a strategy solely
targeting AB clearance does not fully correlate with improvements
in patients cognitive function.
|